Glenn S Tillotson
Senior Partner, tranScrip
Senior Scientific Advisor of Optimer Pharmaceuticals Inc
Glenn is a Senior Partner at TranScrip Partners USA. He is trained in medical microbiology and infectious diseases and has over 25 years of pharmaceutical industry experience in various areas including clinical research, commercialization, scientific communications including publication planning, strategic drug development, life cycle management and global launch programs. Glenn has been instrumental in the development of ciprofloxacin and moxifloxacin as well as other drugs in the Bayer portfolio for whom he worked for 15 years. After leaving Bayer he worked as a consultant microbiologist and later joined Oscient, during which time he was involved in the commercialization and launch of gemifloxacin (Factive) in the US as well as co-marketing and business development deals globally. In 2006 he joined Replidyne as Executive Director of Scientific Affairs and worked on the company’s anti-infective portfolio, including faropenem. In 2008 Glenn became the Head of Medical Affairs at ViroPharma where he oversaw educational, publication and other related activities for Vancocin, maribavir and Cinryze. He later worked for Optimer Pharmaceuticals as Senior Vice President of Medical Affairs and built a team to support the launch of fidaxomicin (Dificid) which has been one of the most successful antibiotic launches ever. Glenn is a member of the Scientific Steering Committee for the GTCBio Annual Summit on Anti-infective Partnering as well as the Anaerobe Society. He is also Chair of the ACCP Chest Infection Network and a member of the ACCP Executive Council of Networks. In 2009 Glenn was honored by the American College of Chest Physicians with the Alfred Soffer Award for contributions to the College. He has published over 140 peer-reviewed manuscripts, presented >270 scientific posters, wrote 5 book chapters and is editing a upcoming e-book on Clostridium difficile. Glenn is on several journal Editorial Advisory Boards including the Lancet Infectious Disease and F1000.
strategic drug development life cycle management